NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DA-23-061 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged.
Funding Opportunity RFA-DA-23-062 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged.
Funding Opportunity RFA-CA-22-056 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.
Funding Opportunity RFA-CA-22-057 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.
Funding Opportunity RFA-MH-22-290 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support a group of large-scale Comprehensive Centers that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases of human and non-human primates with an emphasis on human. The Centers are expected to characterize all brain cell types (neurons, glia, and other non-neuronal cells) at high-resolution. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.
Funding Opportunity RFA-MH-22-292 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases in human, non-human primates, and mouse, in coordination and collaboration with other BICAN projects. In particular, the Specialized Collaboratories are expected to complement the Comprehensive Centers in BICAN with distinct capabilities, competencies, and research aims. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.
Funding Opportunity RFA-MH-22-291 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support a Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE) that will be composed of four components to establish respectively (1) a common sequencing data processing pipeline, (2) a common imaging data processing pipeline, (3) a comprehensive brain cell knowledge base, and (4) an engaging and outreach component to coordinate the research within and beyond BICAN. The overall goals of CUBIE are to (i) enable the exploration of large-scale brain cell atlas data and knowledge, and inspire research in brain function and disorders; and (ii) ensure research rigor and data reproducibility by making the data to be findable, accessible, interoperable, and reusable, and the process transparent. An application is expected to propose only one of the above four respective components.
Funding Opportunity RFA-CA-22-051 from the NIH Guide for Grants and Contracts. The HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network seeks to evaluate innovative approaches for overcoming barriers and reducing failures in the cervical cancer screening and treatment cascade for women living with HIV. The proposed multicenter network will conduct pragmatic clinical trials to evaluate the effectiveness of clinically proven interventions in intended-use settings with a goal to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. These trials will focus on the health care continuum for secondary cervical cancer prevention, i.e., increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments. Data from these trials will be used to provide the necessary evidence to refine clinical practice guidelines and inform public health policy with a goal to generate crucial actionable evidence for improving cervical cancer prevention implementation programs. Six-to-eight UG1 cooperative agreement mechanism-funded Clinical Sites, led by clinical investigators and/or clinicians, will provide a pluripotent clinical infrastructure to conduct/implement multiple prevention clinical trials through the CASCADE network and interface with network grantees during concept and protocol development to provide insights and input on clinical significance and study feasibility.
Funding Opportunity RFA-AG-23-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease (AD) and AD-related dementias (ADRD). Mechanisms of adherence may be studied in new, early- to late-stage (including Stage I-IV) behavior change trials. Applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that, if modified, will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD. This FOA utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase will support pilot research to identify, measure, and assess the malleability of psychological or interpersonal adherence-relevant targets that, if successful, can transition to the R33 phase. The R33 phase will utilize results from the R61 phase to implement rigorous, proof-of-concept intervention studies. The transition from the R61 to the R33 phase will be administratively reviewed for, and be dependent upon, successful completion of the go/no-go criteria specified for the R61 phase.
Funding Opportunity RFA-CA-22-042 from the NIH Guide for Grants and Contracts. The purpose of this RFA is to stimulate research on the development and evaluation of tobacco cessation interventions for adolescents, with an emphasis on ages 14-20. We have chosen to focus on this developmental period because it represents the area of greatest need with respect to the existing evidence on use patterns and treatment gaps. It also targets the developmental risk period for which we will see the maximum benefit from early intervention.
Notice NOT-ES-23-002 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-221 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-043 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support studies that develop, test, implement, and evaluate behavioral tobacco cessation interventions for adolescents, with a focus on the critical developmental risk period of mid- to late-adolescence (approximately 14-20 years old).
Funding Opportunity RFA-ES-22-008 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity announcement (FOA) is to solicit applications that propose to better understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence, or early adulthood. Since basic and pre-clinical research is critical for the study of neurobiological mechanisms that drive complex behaviors including mental illness, the focus of this FOA is to encourage a range of mechanistic approaches, from in vitro systems to whole organism models, to examine the link between environmental chemicals and possible contribution to the pathogenesis of psychiatric abnormalities. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are also welcomed. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. This FOA will use the NIH Research Project Grant (R01) award mechanism and runs in parallel with the companion FOA, RFA-ES-22-009, which encourages applications under the R21 mechanism.
Funding Opportunity RFA-ES-22-009 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity announcement (FOA) is to solicit applications that propose to better understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence, or early adulthood. The R21 grant mechanism is intended to encourage exploratory and developmental research projects that are high-risk and/or use novel approaches with potential for significant impact. Investigations that further advance our understanding of psychiatric conditions where there is less evidence of an environmental exposure link are of particular interest. Since basic and pre-clinical research is critical for the study of neurobiological mechanisms that drive complex behaviors including mental illness, the focus of this FOA is to encourage a range of mechanistic approaches, from in vitro systems to whole organism models, to examine the link between environmental chemicals and possible contribution to the pathogenesis of psychiatric abnormalities. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are also welcomed. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. This FOA will use the NIH Exploratory/Developmental Research Grant (R21) award mechanism and runs in parallel with another FOA, RFA-ES-22-008, which encourages applications under the R01 mechanism.
Notice NOT-HS-22-024 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-052 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), NCI, NIDA, and NCCIH invite Cooperative Agreement (U01) applications that propose prospective research studies to assess the benefits and harms of cannabis and cannabinoid use among adult cancer patients during active treatment. NCI, NIDA, and NCCIH are seeking well-designed prospective cohort studies of cancer patients with solid or hematologic tumors currently receiving treatment. Studies are expected to compare cancer patients who use cannabis/cannabinoids with cancer patients that do not use cannabis and/or cannabinoids. Research studies including diverse populations by age, sex, race/ethnicity, tumor types, and/or geography and propose population-based recruitment strategies using cancer registries are strongly encouraged. This FOA is published in parallel with RFA-CA-22-053 "Coordinating Center for Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed). New prospective studies and the coordinating center funded under these FOAs will work together with NIH program staff.
Notice NOT-HS-22-025 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-028 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-224 from the NIH Guide for Grants and Contracts